Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy
The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2008 by University Hospital Birmingham.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
University Hospital Birmingham
Information provided by:
University Hospital Birmingham
ClinicalTrials.gov Identifier:
NCT00698074
First received: June 11, 2008
Last updated: June 13, 2008
Last verified: June 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary aim of this study will be to assess whether Biventricular pacing improves exercise capacity, and Quality of Life in patients with symptomatic drug resistant Non-Obstructive Hypertrophic Cardiomyopathy, using a Biventricular pacemaker.
| Condition | Intervention | Phase |
|---|---|---|
|
Hypertrophic Cardiomyopathy |
Device: Cardiac Resynchronisation Therapy |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy |
Resource links provided by NLM:
Genetics Home Reference related topics:
familial hypertrophic cardiomyopathy
supravalvular aortic stenosis
U.S. FDA Resources
Further study details as provided by University Hospital Birmingham:
| Estimated Enrollment: | 32 |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Cardiac Resynchronisation Therapy
|
Device: Cardiac Resynchronisation Therapy
Biventricular Pacemaker Implant
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Symptomatic Hypertrophic Cardiomyopathy,
Exclusion Criteria:
- Rhythm other than normal sinus Left ventricular outflow tract gradient greater than 30mmHg Inability to exercise v02 max greater than 70% of predicted.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00698074
Contacts
| Contact: Michael P Frenneaux, MBBS | 121-414-5916 ext 5916 | m.p.frenneaux@bham.ac.uk |
Locations
| United Kingdom | |
| Department Cardiovascular Medicine, University of Birmingham | Recruiting |
| Birmingham, West Midlands, United Kingdom, B15 2TT | |
| Contact: ibrar ahmed, MBChB 121-414-5916 01ahmedi@gmail.com | |
Sponsors and Collaborators
University Hospital Birmingham
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00698074 History of Changes |
| Other Study ID Numbers: | 05/Q2709/64 |
| Study First Received: | June 11, 2008 |
| Last Updated: | June 13, 2008 |
| Health Authority: | United Kingdom: Research Ethics Committee |
Additional relevant MeSH terms:
|
Cardiomyopathy, Hypertrophic Hypertrophy Cardiomyopathies Heart Diseases Cardiovascular Diseases |
Aortic Stenosis, Subvalvular Aortic Valve Stenosis Heart Valve Diseases Pathological Conditions, Anatomical |
ClinicalTrials.gov processed this record on May 19, 2013